Technology ID
TAB-3813

SARS-CoV-2 Iinfection of Human Lung Epithelial Cells Triggers a Cell-Mediated Acute Fibrin Fibrosis

E-Numbers
E-157-2022-0
Lead Inventor
Sun, Peter (NIAID)
Co-Inventors
Erickson, Rachel (University of Pennsylvania)
Development Stages
Pre-Clinical (in vitro)
Lead IC
 
ICs
NIAID
Scientists at NIAID have developed a method of treatment for virus-induced lung fibrosis using nebulized thrombin inhibitors. Since March 2020, the WHO estimates that 564 million people have been infected with SARS-CoV-2 world-wide. Lung fibrosis is a major factor associated with SARS-CoV-2 infections and can contribute to mortality. Additionally, severe SARS-CoV-2 cases can result in long-term pulmonary disease due to lung fibrosis. At present, attempts to treat lung fibrosis developed during a SARS-CoV-2 infection using intravenous heparin have been unsuccessful.

NIAID scientists have discovered a previously unknown acute fibrosis mechanism mediated by SARS-CoV-2 infected primary lung epithelium, and have developed an innovative method of treating lung fibrosis using nebulized thrombin inhibitors.
Commercial Applications
  • Innovative method of treatment for virus-induced lung fibrosis
  • A multi-targeted approach could decrease lung-term symptoms associated with SARS-CoV-2
Competitive Advantages
  • Addresses the pathology at the proper location instead of indiscriminately
Licensing Contact:
Taylor-Mulneix, Dawn
dawn.taylor-mulneix@nih.gov
Phone: 301-761-6958